Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Launched by UNIVERSITY OF TURIN, ITALY · Nov 27, 2024
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to monitor patients who have received a life-saving treatment called allogeneic hematopoietic stem cell transplantation (HSCT). This treatment can help people with serious blood-related diseases, but it carries risks, including a condition known as graft-versus-host disease (GVHD), where the transplanted cells attack the patient's own body. The trial is exploring whether analyzing small pieces of DNA found in the blood, called cell-free DNA (cfDNA), can help doctors detect complications like GVHD, infections, and the return of the original disease earlier and more effectively than current methods.
To participate in this study, patients must be between 18 and 74 years old and have a blood cancer that requires HSCT. The trial is currently looking for volunteers. If you join, you can expect to undergo tests that analyze your cfDNA, which could provide valuable insights into your health after the transplant. The hope is that this research will lead to better, less invasive ways to monitor patients, ultimately improving their outcomes and reducing complications after HSCT.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient must be affected by an hematological malignancy requiring hematopoietic stem cell transplantation (HSCT).
- Exclusion Criteria:
- • Patients can not be 17 years old or yunger
About University Of Turin, Italy
The University of Turin, located in Italy, is a prestigious academic institution renowned for its commitment to research and innovation in the medical field. As a clinical trial sponsor, the university leverages its extensive expertise and resources to advance scientific knowledge and improve patient outcomes. Collaborating with a network of healthcare professionals and researchers, the University of Turin conducts rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its focus on translational research ensures that findings contribute to the development of effective therapies and healthcare solutions, enhancing the overall well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Turin, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported